Global BulletinAll NewsFDA Approval AlertWomen in Oncology
Expert InterviewsAround the PracticeBetween the LinesFace OffFrom All AnglesMeeting of the MindsOncViewPodcastsTraining AcademyTreatment Algorithms with the Oncology BrothersVideos
Conferences
All JournalsEditorial BoardFor AuthorsYear in Review
Frontline ForumSatellite Sessions
CME/CE
Awareness MonthInteractive ToolsNurse Practitioners/Physician's AssistantsPartnersSponsoredSponsored Media
Career CenterSubscribe
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
Spotlight -
  • Radiation Oncology
  • Surgery
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
    • Conferences
    • CME/CE
    • Career Center
    • Subscribe
Advertisement

No Link Found Between PCB Exposure and Cancer Mortality

May 1, 1999
Publication
Article
OncologyONCOLOGY Vol 13 No 5
Volume 13
Issue 5

In the largest human study of its kind, researchers Renate D. Kimbrough, MD, and Martha L. Doemland,PhD, have found

In the largest human study of its kind, researchers Renate D. Kimbrough, MD, and Martha L. Doemland,PhD, have found no association between actual human exposure to polychlorinated biphenyls (PCBs) and death from cancer or any other diseases.

For more than 20 years, the federal government has characterized PCBs as probable human carcinogens based, in part, on Dr. Kimbrough’s 1975 study of PCBs in rats fed a diet containing large quantities of the substance. “This new study provides strong evidence that even long-term human exposure to PCBs at higher levels than are found in the environment is not related to an increase in deaths from cancer or any other diseases,” said Dr. Kimbrough, the study’s principal investigator and a senior medical associate with the Institute for Evaluating Health Risks (IEHR) in Washington, DC.

The findings of the study, published in the March 1999 issue of the Journal of Occupational and Environmental Medicine, are consistent with those of four other studies of the same population conducted by other researchers over a span of nearly 25 years. However, the current study is the largest and most statistically powerful one to date.

Study Data

The study focused on 7,075 men and women who worked between 1946 and 1977 in two upstate New York General Electric factories that used PCBs in manufacturing electrical capacitors. The study compared the number (1,195) and causes of death within the study population to national and regional averages. The average follow-up time for study members was 31 years, providing a sufficiently long latency period in which to determine whether there was any increase in cancer mortality.

Some of the workers in the study had PCB levels in their blood as high as several thousand parts per billion—well above the average PCB levels found in the blood of people in the United States who have been tested (average PCB levels range from four to eight parts per billion, according to the Agency for Toxic Substances and Disease Registry).

Dr. John A. Moore, president of IEHR, said: “The findings of this study are consistent with a belief that cancer risks from exposure to PCBs have been overstated. The newer laboratory data of the past several years support such a view and also prompted the EPA to reduce the factors they use to estimate PCB cancer risks.”

Smaller Trials Confirm Validity of Current Findings

Dr. Arthur C. Upton, former director of the National Cancer Institute and currently a professor at the Robert Wood Johnson Medical School, said of the study: “This is a significant study that should be factored into any public discussion of PCBs and human health. Dr. Kimbrough and her colleagues were meticulous in their efforts to gather and verify information on the 7,075 individuals who were part of the investigation. The analysis of the data and conclusions are scientifically appropriate and the authors are to be complemented on the high quality of their study and report as well as the publication that was prepared from this information.”

Dr. Upton chaired a five-member advisory committee established by the IEHR to review the design, execution, analysis, and interpretation of the study.

“This was a well-designed and carefully conducted study,” said Dr. Jack Mandel, an epidemiologist and professor and director of environmental and occupational health at the University of Minnesota.

The study’s findings are consistent with shorter-term studies of workers in the same factories conducted by the National Institute for Occupational Safety and Health, Harvard School of Public Health, the New York State Department of Health, and the Mt. Sinai School of Medicine.

The IEHR conducted the study at the request of and with funding from General Electric, which operates the businesses where the workers were employed. General Electric had no role in the conduct of the study, the evaluation of the data, or the conclusions drawn, said Dr. Kimbrough.

Articles in this issue

Thalidomide Shows Promising Results in Patients With Multiple Myeloma
Bill Would Allow Medicaid to Pay for Cervical/Breast Cancer Treatment
Photodynamic Therapy for Palliation of Locally Advanced Lung Cancer
Increased NIH Funding Needed to Combat Cancer in Minorities, Medically Underserved
Zeneca Launches Education Program Aimed at Reducing Breast Cancer Risk
Reinventing Bone Marrow Transplantation
Age Should Not Determine Treatment of SCLC Patients
Single Chest X-Ray Leads to Improved Lung Cancer Prognosis
No Link Found Between PCB Exposure and Cancer Mortality
Arsenic Induces Remissions in Patients With Acute Promyelocytic Leukemia
Cancer Outreach Programs for African-Americans
A 38-Year-Old Man With Pancreatic Cancer
ELVIS Study Results Offer Hope to Elderly Lung Cancer Patients
ASCO President Presses Medicare to Cover Costs of Cancer Clinical Trial Participants
Future Target for HIV Therapy: T-Cell’s Own Proteins
Recent Videos
The investigational agent exhibited superior efficacy vs pembrolizumab in patients with lung cancer, suggesting potential efficacy in kidney cancer.
Management of adverse effects and access to cellular therapies among community oncologists represented key points of discussion in multiple myeloma.
2 experts are featured in this series.
2 experts are featured in this series.
1 expert is featured in this series.
1 expert is featured in this series.
“As a community, if we’re looking to help enroll and advocate for patients with rare [kidney cancers], we need to be aware of what is out there,” said A. Ari Hakimi, MD.
Treatment with the dual inhibitor displayed a short half-life and a manageable toxicity profile in patients with clear cell renal cell carcinoma.
The annual Kidney Cancer Research Summit was born from congressional funding for kidney cancer research, according to KidneyCAN president Bryan Lewis.
Combining renal vaccines with immune therapy may better target tumor cells while limiting harm to healthy tissue, according to David A. Braun, MD, PhD.
Related Content
Advertisement

SAR446523 is currently being evaluated in a first-in-human, phase 1 trial in patients with pretreated relapsed/refractory multiple myeloma.

FDA Grants Orphan Drug Designation to GPRC5D Target in Multiple Myeloma

Tim Cortese
July 30th 2025
Article

SAR446523 is currently being evaluated in a first-in-human, phase 1 trial in patients with pretreated relapsed/refractory multiple myeloma.


Experts share their perspectives on updated clinical trial results, personalized cancer vaccine research, and other notable developments in kidney cancer.

Key Advances Across Kidney Cancer Research and Management at KCRS 2025

Thomas Powles, MBBS, MCRP, MD;David Braun, MD, PhD;Wenxin (Vincent) Xu, MD;Eric Jonasch, MD
July 28th 2025
Podcast

Experts share their perspectives on updated clinical trial results, personalized cancer vaccine research, and other notable developments in kidney cancer.


Choosing Between HLA-Mismatched Unrelated and Haploidentical Donors: Donor Age Considerations

Choosing Between HLA-Mismatched Unrelated and Haploidentical Donors: Donor Age Considerations

American Society for Transplantation and Cellular Therapy
July 30th 2025
Article

Researchers have found that donor age is a key determinant of outcomes in hematopoietic cell transplantation, with younger donors associated with significantly better survival and lower rates of GVHD.


Leading experts in the breast cancer field highlight the use of CDK4/6 inhibitors, antibody-drug conjugates, and other treatment modalities.

Advancements and Evolving Strategies in Breast Cancer Treatment at IBC East

Heather McArthur, MD, MPH;Erika P. Hamilton, MD;Hope S. Rugo, MD;Paolo Tarantino, MD, PhD
July 21st 2025
Podcast

Leading experts in the breast cancer field highlight the use of CDK4/6 inhibitors, antibody-drug conjugates, and other treatment modalities.


Phase 2 CRDF-004 results revealed that the addition of onvansertib to chemotherapy/bevacizumab was well-tolerated, with no unexpected toxicities observed.

Onvansertib Exhibits Encouraging Responses in RAS-Mutant Metastatic CRC

Roman Fabbricatore
July 30th 2025
Article

Phase 2 CRDF-004 results revealed that the addition of onvansertib to chemotherapy/bevacizumab was well-tolerated, with no unexpected toxicities observed.


Innovative oncolytic virus therapies transform advanced melanoma treatment, enhance patient outcomes, and overcome resistance to traditional immunotherapies.

3 Things You Should Know About Managing Advanced Melanoma With Oncolytic Viral Immunotherapies

ONCOLOGY Staff
July 30th 2025
Article

Innovative oncolytic virus therapies transform advanced melanoma treatment, enhance patient outcomes, and overcome resistance to traditional immunotherapies.

Related Content
Advertisement

SAR446523 is currently being evaluated in a first-in-human, phase 1 trial in patients with pretreated relapsed/refractory multiple myeloma.

FDA Grants Orphan Drug Designation to GPRC5D Target in Multiple Myeloma

Tim Cortese
July 30th 2025
Article

SAR446523 is currently being evaluated in a first-in-human, phase 1 trial in patients with pretreated relapsed/refractory multiple myeloma.


Experts share their perspectives on updated clinical trial results, personalized cancer vaccine research, and other notable developments in kidney cancer.

Key Advances Across Kidney Cancer Research and Management at KCRS 2025

Thomas Powles, MBBS, MCRP, MD;David Braun, MD, PhD;Wenxin (Vincent) Xu, MD;Eric Jonasch, MD
July 28th 2025
Podcast

Experts share their perspectives on updated clinical trial results, personalized cancer vaccine research, and other notable developments in kidney cancer.


Choosing Between HLA-Mismatched Unrelated and Haploidentical Donors: Donor Age Considerations

Choosing Between HLA-Mismatched Unrelated and Haploidentical Donors: Donor Age Considerations

American Society for Transplantation and Cellular Therapy
July 30th 2025
Article

Researchers have found that donor age is a key determinant of outcomes in hematopoietic cell transplantation, with younger donors associated with significantly better survival and lower rates of GVHD.


Leading experts in the breast cancer field highlight the use of CDK4/6 inhibitors, antibody-drug conjugates, and other treatment modalities.

Advancements and Evolving Strategies in Breast Cancer Treatment at IBC East

Heather McArthur, MD, MPH;Erika P. Hamilton, MD;Hope S. Rugo, MD;Paolo Tarantino, MD, PhD
July 21st 2025
Podcast

Leading experts in the breast cancer field highlight the use of CDK4/6 inhibitors, antibody-drug conjugates, and other treatment modalities.


Phase 2 CRDF-004 results revealed that the addition of onvansertib to chemotherapy/bevacizumab was well-tolerated, with no unexpected toxicities observed.

Onvansertib Exhibits Encouraging Responses in RAS-Mutant Metastatic CRC

Roman Fabbricatore
July 30th 2025
Article

Phase 2 CRDF-004 results revealed that the addition of onvansertib to chemotherapy/bevacizumab was well-tolerated, with no unexpected toxicities observed.


Innovative oncolytic virus therapies transform advanced melanoma treatment, enhance patient outcomes, and overcome resistance to traditional immunotherapies.

3 Things You Should Know About Managing Advanced Melanoma With Oncolytic Viral Immunotherapies

ONCOLOGY Staff
July 30th 2025
Article

Innovative oncolytic virus therapies transform advanced melanoma treatment, enhance patient outcomes, and overcome resistance to traditional immunotherapies.

Advertisement
About
Advertise
CureToday.com
OncLive.com
OncNursingNews.com
TargetedOnc.com
Editorial
Contact
Terms and Conditions
Privacy
Do Not Sell My Personal Information
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.